Alissa Visram

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/5842037/publications.pdf

Version: 2024-02-01

		1163117	1199594
34	174	8	12
papers	citations	h-index	g-index
35	35	35	279
all docs	docs citations	times ranked	citing authors

#	Article	IF	CITATIONS
1	Outcomes after biochemical or clinical progression in patients with multiple myeloma. Blood Advances, 2023, 7, 909-917.	5.2	7
2	Family history of plasma cell disorders is associated with improved survival in MGUS, multiple myeloma, and systemic AL amyloidosis. Leukemia, 2022, 36, 1058-1065.	7.2	3
3	Monoclonal proteinuria predicts progression risk in asymptomatic multiple myeloma with a free light chain ratio ≥100. Leukemia, 2022, 36, 1429-1431.	7.2	8
4	Success of the autologous stem cell boost after autologous graft failure in multiple myeloma and AL amyloidosis. Bone Marrow Transplantation, 2022, , .	2.4	O
5	Body mass index associated with monoclonal gammopathy of undetermined significance (MGUS) progression in Olmsted County, Minnesota. Blood Cancer Journal, 2022, 12, 67.	6.2	13
6	Prognostic value of NT-ProBNP and troponin T in patients with light chain amyloidosis and kidney dysfunction undergoing autologous stem cell transplantation. Bone Marrow Transplantation, 2021, 56, 274-277.	2.4	1
7	Outcomes of multiple myeloma patients with <scp>del 17p</scp> undergoing autologous stem cell transplantation. American Journal of Hematology, 2021, 96, E35-E38.	4.1	2
8	Autologous stem cell transplantation for multiple myeloma patients aged ≥ 75 treated with novel agents. Bone Marrow Transplantation, 2021, 56, 1144-1150.	2.4	15
9	Prognostic Implications of Rising Serum Monoclonal Protein and Free Light Chains after Autologous Stem Cell Transplantation in Patients with Multiple Myeloma. Transplantation and Cellular Therapy, 2021, 27, 309.e1-309.e5.	1.2	1
10	Retroperitoneal involvement with light chain amyloidosis- case series and literature review. Leukemia and Lymphoma, 2021, 62, 316-322.	1.3	2
11	Practical management and assessment of primary plasma cell leukemia in the novel agent era. Cancer Treatment and Research Communications, 2021, 28, 100414.	1.7	1
12	Disease monitoring with quantitative serum IgA levels provides a more reliable response assessment in multiple myeloma patients. Leukemia, 2021, 35, 1428-1437.	7.2	8
13	Relapsed multiple myeloma demonstrates distinct patterns of immune microenvironment and malignant cell-mediated immunosuppression. Blood Cancer Journal, 2021, 11, 45.	6.2	24
14	Serum BCMA levels predict outcomes in MGUS and smoldering myeloma patients. Blood Cancer Journal, 2021, 11, 120.	6.2	18
15	Treatment and outcome of newly diagnosed multiple myeloma patients > 75 years old: a retrospective analysis. Leukemia and Lymphoma, 2021, 62, 3011-3018.	1.3	2
16	Aging-associated immune system changes in multiple myeloma: The dark side of the moon Cancer Treatment and Research Communications, 2021, 29, 100494.	1.7	6
17	Prognostic Role of IL-6 in POEMS Syndrome. Blood, 2021, 138, 2700-2700.	1.4	0
18	Monoclonal Proteinuria Predicts Progression Risk in Asymptomatic Multiple Myeloma with a Free Light Chain Ratio ≥100. Blood, 2021, 138, 1617-1617.	1.4	0

#	Article	IF	CITATIONS
19	Assessing the prognostic utility of smoldering multiple myeloma risk stratification scores applied serially post diagnosis. Blood Cancer Journal, 2021, 11, 186.	6.2	8
20	Outcomes Following Biochemical or Clinical Progression in Patients with Multiple Myeloma. Blood, 2021, 138, 3760-3760.	1.4	1
21	Prognostic Factors for Early (<2 years) and Late (>5 years) Relapse in Multiple Myeloma-Pivotal Role of Cytogenetic Changes. Blood, 2021, 138, 3761-3761.	1.4	0
22	Assessing the Prognostic Utility of the Mayo 2018 and IMWG 2020 Smoldering Multiple Myeloma Risk Stratification Scores When Applied Post Diagnosis. Blood, 2021, 138, 543-543.	1.4	0
23	Colon perforation in multiple myeloma patients – A complication of highâ€dose steroid treatment. Cancer Medicine, 2020, 9, 8895-8901.	2.8	3
24	Plerixafor in combination with chemotherapy and/or hematopoietic cell transplantation to treat acute leukemia: A systematic review and metanalysis of preclinical and clinical studies. Leukemia Research, 2020, 97, 106442.	0.8	15
25	Correlation between urine ACR and 24-h proteinuria in a real-world cohort of systemic AL amyloidosis patients. Blood Cancer Journal, 2020, 10, 124.	6.2	12
26	Increased Bone Marrow Plasma-Cell Percentage Predicts Outcomes in Newly Diagnosed Multiple Myeloma Patients. Clinical Lymphoma, Myeloma and Leukemia, 2020, 20, 596-601.	0.4	15
27	Treatments and Outcomes of Newly Diagnosed Multiple Myeloma Patients > 75 Years Old: A Retrospective Analysis. Blood, 2020, 136, 14-15.	1.4	0
28	Outcomes of Multiple Myeloma Patients with Del 17p Undergoing Autologous Stem Cell Transplantation. Blood, 2020, 136, 21-22.	1.4	0
29	Autologous Stem Cell Transplantation for Multiple Myeloma Patients Aged ≥ 75 Treated with Novel Agents. Blood, 2020, 136, 12-13.	1.4	0
30	Retroperitoneal Involvement of Light Chain Amyloidosis-Case Series and Literature Review. Blood, 2020, 136, 37-38.	1.4	0
31	Prevalence of Familial Plasma Cell Disorders in Patients with Multiple Myeloma. Blood, 2020, 136, 1-2.	1.4	0
32	Decreased Cardiac Ejection Fraction Is Associated with Worse Survival in Patients with Light Chain Amyloidosis Treated with Autologous Stem Cell Transplantation. Blood, 2020, 136, 41-42.	1.4	0
33	Describing the Cellular and Humoral Immune Tumor Microenvironment and Malignant Transcriptome across the Multiple Myeloma Disease Spectrum. Blood, 2020, 136, 39-40.	1.4	2
34	Effect of Donor Age and Donor Relatedness on Time to Allogeneic Hematopoietic Cell Transplantation in Acute Leukemia. Biology of Blood and Marrow Transplantation, 2018, 24, 2466-2470.	2.0	7